U.S. markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.81%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • GBP/USD

    1.3922
    -0.0091 (-0.65%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.30%)
     
  • BTC-USD

    47,441.43
    +66.75 (+0.14%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / September 25, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Sarepta Therapeutics, Inc. (SRPT)
Class Period: September 6, 2017 - August 19, 2019

Deadline: October 29, 2019
For more info:www.bgandg.com/srpt

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) golodirsen posed significant safety risks to patients; (2) consequently, the NDA package for golodirsen's accelerated approval was unlikely to receive FDA approval; and (3) as a result, Sarepta's public statements were materially false and misleading at all relevant times.

Aclaris Therapeutics, Inc. (ACRS)

Class Period: May 8, 2018 - June 20, 2019

Deadline: October 30, 2019
For more info:www.bgandg.com/acrs

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) the Company's advertising materials minimized the risks and overstated the efficacy of ESKATA to generate sales; (2) as a result, the Company was reasonably likely to face regulatory scrutiny; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Canada Goose Holdings Inc. (GOOS)

Class Period: March 16, 2017 - August 1, 2019

Deadline: November 4, 2019
For more info:www.bgandg.com/goos

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Canada Goose sourced the down and fur used in its clothing products in a way that treated animals in an unethical and inhumane manner; (2) Canada Goose was thus non-compliant with relevant FTC regulations pertaining to false advertising with respect to its sourcing practices; (3) accordingly, Canada Goose was the subject of an ongoing FTC investigation regarding false advertising; and (4) consequently, the Company's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/560613/Sarepta-Therapeutics-Inc-SRPT-Aclaris-Therapeutics-Inc-ACRS-Canada-Goose-Holdings-Inc-GOOS--Class-Action-Update--Bronstein-Gewirtz-Grossman-LLC